PTK2 and neoplasm: Although these studies provide compelling data supporting a role for FAK in ErbB2 tumour progression, whether FAK is required in vivo for ErbB2 mammary tumour progression has not been addressed; this question is imperative given that the integrin/FAK signalling output from ErbB2 tumour cells is highly dependent on the microenvironment within the mammary fat pad.